Reversing tau pathology to improve serotonin function in early Alzheimer's disease
Official title: Reversal of Tau Pathology to Rescue Serotonergic Function in Early Alzheimer’s Disease
Funded at University of Iowa · NIH-10902655 · Data updated 2026-11-12
This study is looking at whether a special DNA treatment can help fix problems with tau proteins in the brain, which might improve serotonin function and boost brain health for people with early Alzheimer's disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $76,828 |
| NIH project number | 1F32AG084196-01A1 |
| Project ID | NIH-10902655 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early Alzheimer's disease who exhibit symptoms related to serotonin dysfunction.
✕Less likely to help
Patients with advanced Alzheimer's disease or those without tau pathology may not benefit from this research.
What this research studies
This research investigates how reversing tau protein abnormalities in the brain can help restore serotonin function in patients with early Alzheimer's disease. The approach involves delivering a specific DNA treatment to a brain region affected by tau pathology, aiming to reduce the harmful effects of hyper-phosphorylated tau. By targeting this pathology, the study seeks to understand if it can improve cognitive function and overall brain health in affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance cognitive function and quality of life for patients with early Alzheimer's disease.
How similar studies have gone: While the approach of targeting tau pathology is gaining interest, this specific method of using PP2A DNA delivery is novel and has not been extensively tested in human subjects.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Kolling, Louis — University of Iowa
- Study coordinator: Kolling, Louis
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.